[go: up one dir, main page]

ES2531115T3 - Combinaciones de clados de RrgB neumocócicos - Google Patents

Combinaciones de clados de RrgB neumocócicos Download PDF

Info

Publication number
ES2531115T3
ES2531115T3 ES10723798T ES10723798T ES2531115T3 ES 2531115 T3 ES2531115 T3 ES 2531115T3 ES 10723798 T ES10723798 T ES 10723798T ES 10723798 T ES10723798 T ES 10723798T ES 2531115 T3 ES2531115 T3 ES 2531115T3
Authority
ES
Spain
Prior art keywords
seq
acid sequence
amino acid
pneumococcal
combinations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10723798T
Other languages
English (en)
Inventor
Vega Masignani
Michele Anne Barocchi
Monica Moschioni
Paolo Ruggiero
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2531115T3 publication Critical patent/ES2531115T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/09Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/09Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092Streptococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/02Peptides of undefined number of amino acids; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Una composición inmunogénica que comprende al menos dos de: (a) un primer polipéptido que comprende una primera secuencia de aminoácidos, en el que la primera secuencia de aminoácidos comprende una secuencia de aminoácidos (i) que tiene al menos el 90 % de identidad de secuencias con SEC ID Nº: 1 y/o (ii) que consiste en un fragmento de al menos 7 aminoácidos contiguos de SEC ID Nº: 1, y que comprende un epítope de SEC ID Nº: 1; (b) un segundo polipéptido, que comprende una segunda secuencia de aminoácidos, en el que la segunda secuencia de aminoácidos comprende una secuencia de aminoácidos (i) que tiene al menos el 90 % de identidad de secuencias con SEC ID Nº: 2 y/o (ii) que consiste en un fragmento de al menos 7 aminoácidos contiguos de SEC ID Nº: 2, y que comprende un epítope de SEC ID Nº: 2; y/o (c) un tercer polipéptido, que comprende una tercera secuencia de aminoácidos, en el que la tercera secuencia de aminoácidos comprende una secuencia de aminoácidos (i) que tiene al menos el 90 % de identidad de secuencias con SEC ID Nº: 3 y/o (ii) que consiste en un fragmento de al menos 7 aminoácidos contiguos de SEC ID Nº: 3, y que comprende un epítope de SEC ID Nº: 3.
ES10723798T 2009-06-01 2010-06-01 Combinaciones de clados de RrgB neumocócicos Active ES2531115T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21762909P 2009-06-01 2009-06-01
US25442609P 2009-10-23 2009-10-23
US31420310P 2010-03-16 2010-03-16
US31892610P 2010-03-30 2010-03-30
PCT/IB2010/052445 WO2010140119A1 (en) 2009-06-01 2010-06-01 COMBINATIONS OF PNEUMOCOCCAL RrgB CLADES

Publications (1)

Publication Number Publication Date
ES2531115T3 true ES2531115T3 (es) 2015-03-10

Family

ID=42557471

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10723798T Active ES2531115T3 (es) 2009-06-01 2010-06-01 Combinaciones de clados de RrgB neumocócicos

Country Status (16)

Country Link
US (2) US20120076814A1 (es)
EP (1) EP2437777B1 (es)
JP (2) JP6008741B2 (es)
KR (1) KR20120035168A (es)
CN (1) CN102481354A (es)
AU (1) AU2010255356A1 (es)
BR (1) BRPI1011857A2 (es)
CA (1) CA2764022A1 (es)
CO (1) CO6470864A2 (es)
ES (1) ES2531115T3 (es)
IL (1) IL216696A0 (es)
MX (1) MX2011012854A (es)
RU (1) RU2011154363A (es)
SG (1) SG176285A1 (es)
WO (1) WO2010140119A1 (es)
ZA (1) ZA201109046B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012002723A (es) 2009-09-02 2012-04-11 Novartis Ag Composiciones inmunogenicas que incluyen moduladores de la actividad de receptores tipo toll.
CN102695523A (zh) * 2009-09-10 2012-09-26 诺华有限公司 针对呼吸道疾病的组合疫苗
EP2719395A1 (en) 2010-09-01 2014-04-16 Novartis AG Adsorption of immunopotentiators to insoluble metal salts
WO2012072769A1 (en) * 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
EP2652511B8 (en) 2010-12-14 2017-06-28 GlaxoSmithKline Biologicals SA Flow cytometry analysis of materials adsorbed to metal salts
JP6191082B2 (ja) 2011-03-02 2017-09-06 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム より低用量の抗原および/またはアジュバントを有する混合ワクチン
JP2014515035A (ja) 2011-05-17 2014-06-26 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ストレプトコッカス・ニューモニエに対するワクチン
WO2013131983A1 (en) 2012-03-07 2013-09-12 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
AU2013229466A1 (en) 2012-03-07 2014-09-04 Novartis Ag Immunologically useful arginine salts
US9375471B2 (en) 2012-03-08 2016-06-28 Glaxosmithkline Biologicals Sa Adjuvanted formulations of booster vaccines
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637481A (en) * 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US20010016200A1 (en) * 1998-04-23 2001-08-23 Briles David E. Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor
EP1737885A2 (en) * 2004-04-12 2007-01-03 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Method of using adenoviral vectors to induce an immune response
US20060165716A1 (en) * 2004-07-29 2006-07-27 Telford John L Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
WO2006080396A1 (ja) * 2005-01-28 2006-08-03 Shionogi & Co., Ltd. 組換え蛋白質の定量法
MX2008010604A (es) * 2006-02-17 2009-03-05 Novartis Ag Purificacion y uso de pilosidades de streptococcus pneumoniae y proteinas pilosas.
EP2063911A2 (en) * 2006-07-26 2009-06-03 Novartis Ag Immunogenic compositions for gram positive bacteria
CA2671629C (en) * 2006-12-06 2017-08-15 Novartis Ag Vaccines including antigen from four strains of influenza virus
GB0714963D0 (en) * 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
AP2010005284A0 (en) * 2007-11-02 2010-06-30 Univ Johns Hopkins Multitype HPV peptide compositions and methods fortreatment or prevention of human papillomavirus i nfection

Also Published As

Publication number Publication date
US20120076814A1 (en) 2012-03-29
US8609106B2 (en) 2013-12-17
KR20120035168A (ko) 2012-04-13
AU2010255356A1 (en) 2011-12-22
BRPI1011857A2 (pt) 2016-03-29
RU2011154363A (ru) 2013-07-20
US20110020385A1 (en) 2011-01-27
ZA201109046B (en) 2013-05-29
MX2011012854A (es) 2011-12-16
WO2010140119A1 (en) 2010-12-09
JP2015227376A (ja) 2015-12-17
CN102481354A (zh) 2012-05-30
JP2012528848A (ja) 2012-11-15
SG176285A1 (en) 2012-01-30
CA2764022A1 (en) 2010-12-09
IL216696A0 (en) 2012-02-29
EP2437777B1 (en) 2014-09-17
EP2437777A1 (en) 2012-04-11
JP6008741B2 (ja) 2016-10-19
CO6470864A2 (es) 2012-06-29

Similar Documents

Publication Publication Date Title
ES2531115T3 (es) Combinaciones de clados de RrgB neumocócicos
ES2542853T3 (es) Método para tratar miastenia grave
ES2563646T3 (es) Composiciones y métodos relacionados con variantes de la proteína A (SpA)
CY1122178T1 (el) Πολυπεπτιδια
ES2540858T3 (es) Composición farmacéutica para el tratamiento y/o la prevención de cáncer
EA201270517A1 (ru) Микобактериальные вакцины
AR107020A2 (es) Vacuna de pcsk9 (proteína convertasa subtilisina-kexina tipo 9)
ES2545895T3 (es) Proteína de fusión anticancerígena
AR085167A1 (es) Polipeptidos de porphyromonas gingivalis, metodo de tratamiento, uso, anticuerpo y kit
CY1119916T1 (el) Ανοσογονικη συνθεση
ES2691539T3 (es) Luciferasas de Oplophorus sintéticas con mayor emisión de luz
CL2013003416A1 (es) Secuencia de peptidos quiméricos que comprende dsspl o dasph composiciones , usos y metodo para mejorar metabolismo de glucosa.
EP2865387A3 (en) Priming of an immune response
ES2530777T3 (es) Vacunas peptídicas para cánceres que expresan antígenos asociados a tumores
CO6700829A2 (es) Moduladores novedosos y métodos de uso
UA110806C2 (uk) Мікобактеріальна антигенна композиція
ES2545457T3 (es) Vacunas de péptidos para cánceres que expresan los polipéptidos DEPDC1
NZ600690A (en) Fkbp-l and uses thereof
CO6491059A2 (es) Diferenciacion de las celulas madre mesenquimales
EA201000327A1 (ru) Белок
PE20121685A1 (es) Antigeno ndv recombinante y usos del mismo
ES2531290T3 (es) Transferasas y oxidorreductasas, ácidos nucleicos que las codifican y métodos para prepararlas y usarlas
AR067980A1 (es) Peptidos de cdh3 y agentes que los comprenden
RU2022100555A (ru) Новый пептид
EP4353256A3 (en) Induction of cross-reactive cellular response against rhinovirus antigens